This trial is conducted in the United States of America (USA). The aim of the trial is to compare the exposure of two formulations of insulin degludec/insulin aspart (NN5401) in healthy subjects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
26
Each subject will be allocated to two single injections of trial product on two separate dosing visits with each of the two insulin degludec/insulin aspart formulations. The trial products will be administered as a subcutaneous injection (under the skin).
Novo Nordisk Clinical Trial Call Center
Chula Vista, California, United States
Area under the serum insulin degludec concentration-time curve
Time frame: from 0 to 120 hours after single-dose
Maximum observed serum insulin degludec concentration
Time frame: from 0 to 120 hours after single-dose
Area under the serum insulin aspart concentration-time curve
Time frame: from 0 to 12 hours after single-dose
Maximum observed serum insulin aspart concentration
Time frame: from 0 to 12 hours after single-dose
Time to maximum observed serum insulin degludec concentration
Time frame: from 0 to 120 hours after single-dose
Time to maximum observed serum insulin aspart concentration
Time frame: from 0 to 12 hours after single-dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.